- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07700498
PEI-GT Trial for Initial Treatment of Primary Open-Angle Glaucoma With Cataract
Efficacy and Safety of Phacoemulsification Combined With Gonioscopy-Assisted Trabeculotomy as Initial Treatment for Primary Open-Angle Glaucoma With Cataract: A Multicenter Randomized Controlled Trial
The goal of this clinical trial is to learn whether doing phacoemulsification combined with gonioscopy-assisted trabeculotomy as an initial treatment can reduce the burden of glaucoma eye drops in adults with primary open-angle glaucoma and cataract. It will also learn whether this early surgical strategy improves ocular surface health and vision-related quality of life. The main questions it aims to answer are:
Does early combined surgery reduce the need for long-term glaucoma medications? Does early combined surgery improve ocular surface health compared with cataract surgery followed by guideline-based glaucoma eye drops? Does early combined surgery improve vision-related quality of life and anxiety compared with the medication-based treatment strategy? What medical problems or complications do participants have after treatment? Researchers will compare phacoemulsification combined with gonioscopy-assisted trabeculotomy to phacoemulsification followed by guideline-based topical eye pressure-lowering medications.
Participants will:
Undergo cataract surgery with or without gonioscopy-assisted trabeculotomy Attend follow-up visits for 24 months after treatment Have eye pressure, visual acuity, OCT, AS-OCT, visual field, ocular surface, and safety examinations at scheduled visits Complete quality-of-life and anxiety questionnaires at scheduled visits Provide tear samples at selected visits for biomarker testing where applicable
A tanulmány áttekintése
Állapot
Részletes leírás
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Hongyang Zhang, PhD
- Telefonszám: +86-20-62787325
- E-mail: hy3005716@163.com
Tanulmányozza a kapcsolattartók biztonsági mentését
- Név: Yuqiao Zhang, PhD
- E-mail: yqzhang@link.cuhk.edu.hk
Tanulmányi helyek
-
-
-
Guangzhou, Kína
- Toborzás
- Nanfang Hospital, Southern Medical University
-
Kapcsolatba lépni:
- Hongyang Zhang
- Telefonszám: +86-20-62787325
- E-mail: hy3005716@163.com
-
Luzhou, Kína
- Még nincs toborzás
- The Affiliated Hospital of Southwest Medical University
-
Zhengzhou, Kína
- Még nincs toborzás
- The First Affiliated Hospital of Zhengzhou University
-
Kapcsolatba lépni:
- Xin Yang
-
Zhuhai, Kína
- Még nincs toborzás
- Zhuhai Hospital of Guangdong Provincial Hospital of Chinese Medicine
-
-
Ningxia
-
Ningxia, Ningxia, Kína
- Még nincs toborzás
- People's Hospital of Ningxia Hui Autonomous Region
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
- Felnőtt
- Idősebb felnőtt
Egészséges önkénteseket fogad
Leírás
Inclusion Criteria:
- Provides written informed consent voluntarily.
- Age 40 to 85 years.
- Male or female.
- Treatment-naive for glaucoma, with no prior IOP-lowering medication, glaucoma laser procedure, or glaucoma surgery.
- Lens opacity causing decreased visual quality and clinically significant cataract.
- Diagnosis of POAG combined with cataract by the treating ophthalmologist.
- Best-corrected visual acuity of 0.1 or better on the Snellen chart, corresponding to LogMAR 1.0 or less.
- Ability and willingness to complete scheduled follow-up visits and study examinations.
Exclusion Criteria:
- Secondary glaucoma, including uveitic, pseudoexfoliative, pigmentary, steroid-induced, neovascular, traumatic, or other secondary glaucoma.
- Angle-closure glaucoma or narrow angle inconsistent with POAG.
- POAG without visually significant cataract.
- Previous anti-glaucoma medication use, glaucoma surgery, or glaucoma laser treatment.
- Advanced visual field loss, defined as visual field mean deviation worse than -12 dB.
- Severe ocular comorbidity or inability to perform reliable visual acuity testing.
- Known contraindication to required study medications.
- Average RNFL thickness or GCIPL thickness less than 54 micrometers.
- Axial length greater than 26 mm.
- Monocular status or functional vision in only one eye.
- Inability to complete reliable visual field or OCT testing.
- Systemic disease that may affect ocular status or study assessment, including diabetes mellitus, uncontrolled hypertension, malignancy, renal disease, autoimmune disease, neurological disease, liver disease, cardiovascular disease, or systemic inflammatory disease.
- Visual impairment mainly attributable to disease other than POAG or cataract.
- Pregnancy, lactation, or planned pregnancy during the study period.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Egyetlen
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: PEI combined with gonioscopy-assisted trabeculotomy
Participants will undergo phacoemulsification cataract extraction with intraocular lens implantation combined with approximately 120 degrees of ab interno gonioscopy-assisted trabeculotomy during the same surgical session.
Postoperative care will follow the protocol, and rescue IOP-lowering medications may be added if clinically indicated.
|
Phacoemulsification combined with Ab interno trabeculotomy performed under gonioscopic visualization for approximately 120 degrees to incise/open the trabecular meshwork and expose Schlemm canal.
The cutting instrument will be non-device-dependent, such as a Tanito hook, Lanxin knife, Zeng knife, or bent 25-26G needle; KDB is not included as the cutting blade.
|
|
Aktív összehasonlító: PEI combined with conventional IOP-lowering medications
Participants will undergo phacoemulsification cataract extraction with intraocular lens implantation.
Postoperatively, conventional topical IOP-lowering medications will be initiated or adjusted according to guideline-based care and clinical judgment when IOP remains above target.
|
Phacoemulsification combined with guideline-based topical IOP-lowering therapy, generally including prostaglandin analogues unless contraindicated, with beta-blockers, carbonic anhydrase inhibitors, alpha-2 agonists, or other agents added or adjusted according to efficacy, tolerance, contraindications, and clinical judgment.
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Mean change in intraocular pressure from baseline to Month 24
Időkeret: Baseline and Month 24
|
Intraocular pressure will be measured in mmHg, preferably by Goldmann applanation tonometry.
Change will be calculated as Month 24 IOP minus baseline IOP and compared between groups.
|
Baseline and Month 24
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Complete success rate
Időkeret: Month 24
|
Proportion of participants achieving postoperative IOP >5 mmHg and ≤16 mmHg or at least 20 percent IOP reduction from baseline, without additional IOP-lowering medication, without vision-threatening complication, and without additional glaucoma surgery.
|
Month 24
|
|
Qualified success rate
Időkeret: Month 24
|
Proportion of participants achieving postoperative IOP >5 mmHg and ≤16 mmHg or at least 20 percent IOP reduction from baseline, with or without IOP-lowering medication, without vision-threatening complication, and without additional glaucoma surgery.
|
Month 24
|
|
Number of IOP-lowering medications
Időkeret: Baseline, Day 1, Day 7, Month 1, Month 3, Month 6, Month 9, Month 12, Month 18, and Month 24
|
Number and class of topical IOP-lowering medications used at each follow-up visit.
|
Baseline, Day 1, Day 7, Month 1, Month 3, Month 6, Month 9, Month 12, Month 18, and Month 24
|
|
Best-corrected visual acuity
Időkeret: Baseline through Month 24
|
Best-corrected visual acuity will be recorded and converted to LogMAR for analysis.
|
Baseline through Month 24
|
|
Visual field indices
Időkeret: Baseline, Month 6, Month 12, Month 18, and Month 24
|
Humphrey visual field 30-2 SITA Standard indices, including mean deviation and pattern standard deviation, will be recorded with reliability criteria.
|
Baseline, Month 6, Month 12, Month 18, and Month 24
|
|
Retinal nerve fiber layer thickness
Időkeret: Baseline, Month 6, Month 12, Month 18, and Month 24
|
Peripapillary retinal nerve fiber layer thickness will be measured by OCT.
|
Baseline, Month 6, Month 12, Month 18, and Month 24
|
|
Ganglion cell-inner plexiform layer thickness
Időkeret: Baseline, Month 6, Month 12, Month 18, and Month 24
|
Macular ganglion cell-inner plexiform layer thickness will be measured by OCT.
|
Baseline, Month 6, Month 12, Month 18, and Month 24
|
|
Anterior segment parameters by AS-OCT
Időkeret: Baseline, Month 1, Month 3, Month 6, Month 9, Month 12, Month 18, and Month 24
|
AS-OCT parameters may include anterior chamber depth, angle opening distance, trabecular-iris space area, and other protocol-specified anterior segment findings.
|
Baseline, Month 1, Month 3, Month 6, Month 9, Month 12, Month 18, and Month 24
|
|
Ocular surface parameters
Időkeret: Baseline, Month 1, Month 3, Month 6, Month 9, Month 12, Month 18, and Month 24
|
Ocular surface assessment includes lipid layer thickness, tear meniscus height, non-invasive tear break-up time, meibomian gland structure, conjunctival hyperemia, and corneal fluorescein staining.
|
Baseline, Month 1, Month 3, Month 6, Month 9, Month 12, Month 18, and Month 24
|
|
NEI VFQ-25 score
Időkeret: Baseline, Month 6, Month 12, Month 18, and Month 24
|
Vision-related quality of life will be assessed using the National Eye Institute Visual Function Questionnaire-25 total score.
|
Baseline, Month 6, Month 12, Month 18, and Month 24
|
|
GAD-7 score
Időkeret: Baseline, Month 6, Month 12, Month 18, and Month 24
|
Anxiety will be assessed using the Generalized Anxiety Disorder 7-item scale total score.
|
Baseline, Month 6, Month 12, Month 18, and Month 24
|
|
Incidence of adverse events
Időkeret: Day 1 through Month 24
|
Ocular and systemic adverse events and serious adverse events will be recorded, including IOP spike, hypotony, hyphema, corneal edema, anterior chamber inflammation, posterior capsule opacification, infection, and need for additional glaucoma surgery.
|
Day 1 through Month 24
|
|
Health economic indicators
Időkeret: Baseline through Month 24
|
Direct medical costs, medication costs, follow-up costs, complication management costs, and other prespecified economic cost indicators will be summarized.
|
Baseline through Month 24
|
Egyéb eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Tear-fluid biomarker levels
Időkeret: Baseline and Month 24
|
Tear-fluid biomarkers include matrix metalloproteinase (MMP), interleukin-13 (IL-13), and tumor necrosis factor-alpha (TNF-alpha).
|
Baseline and Month 24
|
|
Surgery-drug benefit index
Időkeret: Baseline through Month 24
|
Composite exploratory index integrating IOP control, medication reduction, structural preservation, ocular surface status, quality of life, safety, and economic outcomes.
|
Baseline through Month 24
|
Együttműködők és nyomozók
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Becsült)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- NFEC-2026-303
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .